<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7476354\results\search\drug\results.xml">
  <result pre="antiviral properties and are already used in daily practice. Recently," exact="hydroxychloroquine" post="and baricitinib have been proposed as potential drugs for"/>
  <result pre="fact, there are other immunosuppressants known with antiviral activities, including" exact="cyclosporine" post="A, hydroxyurea, minocycline, mycophenolic acid, mycophenolate mofetil, leflunomide, tofacitinib,"/>
  <result pre="immunosuppressants known with antiviral activities, including cyclosporine A, hydroxyurea, minocycline," exact="mycophenolic acid," post="mycophenolate mofetil, leflunomide, tofacitinib, and thalidomide. The inherent antiviral"/>
  <result pre="with antiviral activities, including cyclosporine A, hydroxyurea, minocycline, mycophenolic acid," exact="mycophenolate mofetil," post="leflunomide, tofacitinib, and thalidomide. The inherent antiviral activity could"/>
  <result pre="for viruses other than SARS-CoV-2 in part II. baricitinib COVID-19" exact="hydroxychloroquine" post="immunosuppressant thalidomide virus Introduction Infections are a common concern"/>
  <result pre="other than SARS-CoV-2 in part II. baricitinib COVID-19 hydroxychloroquine immunosuppressant" exact="thalidomide" post="virus Introduction Infections are a common concern of immunosuppressive"/>
  <result pre="search of the PubMed database using the keywords (chloroquine OR" exact="hydroxychloroquine" post="OR baricitinib OR cyclosporine OR hydroxyurea OR minocycline OR"/>
  <result pre="database using the keywords (chloroquine OR hydroxychloroquine OR baricitinib OR" exact="cyclosporine" post="OR hydroxyurea OR minocycline OR mycophenolic acid OR mycophenolate"/>
  <result pre="the keywords (chloroquine OR hydroxychloroquine OR baricitinib OR cyclosporine OR" exact="hydroxyurea" post="OR minocycline OR mycophenolic acid OR mycophenolate mofetil OR"/>
  <result pre="hydroxychloroquine OR baricitinib OR cyclosporine OR hydroxyurea OR minocycline OR" exact="mycophenolic acid" post="OR mycophenolate mofetil OR leflunomide OR tofacitinib OR thalidomide)"/>
  <result pre="OR cyclosporine OR hydroxyurea OR minocycline OR mycophenolic acid OR" exact="mycophenolate mofetil" post="OR leflunomide OR tofacitinib OR thalidomide) AND (virus OR"/>
  <result pre="hydroxyurea OR minocycline OR mycophenolic acid OR mycophenolate mofetil OR" exact="leflunomide" post="OR tofacitinib OR thalidomide) AND (virus OR viral) was"/>
  <result pre="minocycline OR mycophenolic acid OR mycophenolate mofetil OR leflunomide OR" exact="tofacitinib" post="OR thalidomide) AND (virus OR viral) was performed from"/>
  <result pre="of potential anti-SARS-CoV-2 activity and for modulating the cytokine storm." exact="Chloroquine" post="and hydroxychloroquine Chloroquine (CQ) and hydroxychloroquine (HCQ), both derivatives"/>
  <result pre="anti-SARS-CoV-2 activity and for modulating the cytokine storm. Chloroquine and" exact="hydroxychloroquine" post="Chloroquine (CQ) and hydroxychloroquine (HCQ), both derivatives of 4-aminoquinoline,"/>
  <result pre="activity and for modulating the cytokine storm. Chloroquine and hydroxychloroquine" exact="Chloroquine" post="(CQ) and hydroxychloroquine (HCQ), both derivatives of 4-aminoquinoline, are"/>
  <result pre="modulating the cytokine storm. Chloroquine and hydroxychloroquine Chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ), both derivatives of 4-aminoquinoline, are indicated to treat"/>
  <result pre="compared with control arms.7â€&quot;12 Based on the inhibitory effect of" exact="azithromycin" post="against Ebola and Zika viruses in vitro, and the"/>
  <result pre="tract infections, two French trials which combined the use of" exact="azithromycin" post="and HCQ revealed better efficacy.7,9 However, further studies are"/>
  <result pre="reversed by calcineurin inhibitors MMFMPA Inhibit DHODH and IMPDH âœ&quot;" exact="Thalidomide" post="Suppress pro-inflammatory cytokines (TNF-Î±, IL-8) through inhibition of NF-ÎºB"/>
  <result pre="COVID-19 by artificial intelligence. Intriguingly, other JAK inhibitors such as" exact="tofacitinib" post="and upadacitinib did not illustrate affinities to NAKs.13,16 A"/>
  <result pre="were given either baricitinib 4â€‰mg/day plus lopinavirâ€&quot;ritonavir or antiretroviral plus" exact="hydroxychloroquine" post="(control group) for 2 weeks. Significant improvement of symptoms"/>
  <result pre="as a modulator for cytokine storm syndrome in COVID-19 infections.25" exact="Mycophenolate mofetil" post="and mycophenolic acid Mycophenolic acid (MPA), an active metabolite"/>
  <result pre="for cytokine storm syndrome in COVID-19 infections.25 Mycophenolate mofetil and" exact="mycophenolic acid" post="Mycophenolic acid (MPA), an active metabolite of mycophenolate mofetil"/>
  <result pre="and mycophenolic acid Mycophenolic acid (MPA), an active metabolite of" exact="mycophenolate mofetil" post="(MMF), inhibits inosine monophosphate dehydrogenase (IMPDH), an essential enzyme"/>
  <result pre="might control viral infection by depleting the intracellular pyrimidine pools.28" exact="Thalidomide" post="Thalidomide, a derivative of glutamic acid, is approved for"/>
  <result pre="45-year-old woman with critical symptoms of COVID-19 was treated by" exact="thalidomide" post="100â€‰mg every 24â€‰h. After the first day use of"/>
  <result pre="all decreased to normal range.15 Proposed mechanisms are as follows:" exact="thalidomide" post="inhibits NF-ÎºB, which further suppresses the production of pro-inflammatory"/>
  <result pre="the production of pro-inflammatory cytokines such as tumor necrosis factor" exact="alpha" post="(TNF-Î±) and IL-8, and prevents the cytokine surge. It"/>
  <result pre="and T-cell receptors. Moreover, the sedative and antiemetic property of" exact="thalidomide" post="helps anxious patients calm down, which reduces oxygen consumption.15"/>
  <result pre="has been conducted to investigate the efficacy and safety of" exact="thalidomide" post="as an adjuvant therapy for COVID-19 pneumonia.29 Part II:"/>
  <result pre="immune-based diseases concomitant with viral infection. DrugsVirus Chloroquine/HCQ Baricitinib CsA" exact="Hydroxyurea" post="Minocycline MMF/MPA Leflunomide Tofacitinib Thalidomide Retrovirus â€ƒHIV â–³ â–³"/>
  <result pre="with viral infection. DrugsVirus Chloroquine/HCQ Baricitinib CsA Hydroxyurea Minocycline MMF/MPA" exact="Leflunomide" post="Tofacitinib Thalidomide Retrovirus â€ƒHIV â–³ â–³ â€¢ â€¢ â€¢"/>
  <result pre="infection. DrugsVirus Chloroquine/HCQ Baricitinib CsA Hydroxyurea Minocycline MMF/MPA Leflunomide Tofacitinib" exact="Thalidomide" post="Retrovirus â€ƒHIV â–³ â–³ â€¢ â€¢ â€¢ â€ƒHTLV-1 â€¢"/>
  <result pre="positive and negative results. BKV, BK virus; CMV, cytomegalovirus; CsA," exact="cyclosporine" post="A; DMARDs, disease-modifying anti-rheumatic drugs; DNA, deoxyribonucleic acid; GAK,"/>
  <result pre="Interrupt life cycle from:(1)â€ƒviral protein synthesis(2)â€ƒgag and envelope assembly(3)â€ƒparticle budding" exact="Hydroxyurea" post="HIV (1)â€ƒInhibit DNA synthesis, slowing production of viral DNA(2)â€ƒDeplete"/>
  <result pre="and protein expression via inhibition of cellular IMPDH MERS-CoV Unknown" exact="Leflunomide" post="HSV, HIV, molluscum and verruca, CMV, BKV, RSV Inhibit"/>
  <result pre="assembling Tofacitinib HTLV-1 HTLV-1-induced ATLL is associated with JAK3 mutations;" exact="tofacitinib" post="inhibits JAK3 Thalidomide HHV-8 Unknown, suspect anti-angiogenesis and make"/>
  <result pre="HTLV-1-induced ATLL is associated with JAK3 mutations; tofacitinib inhibits JAK3" exact="Thalidomide" post="HHV-8 Unknown, suspect anti-angiogenesis and make immune system able"/>
  <result pre="et al.,61 Barrows et al.62 Betaretrovirus âœ&quot; Montano-Loza et al.63" exact="Hydroxyurea" post="HIV âœ&quot; Lori and Lisziewicz64 âœ&quot; RCT (nâ€‰=â€‰57): greater"/>
  <result pre="and fatal disease; higher viral loads than the untreated animals96" exact="Leflunomide" post="HSV âœ&quot; Knight et al.97 âœ&quot; nâ€‰=â€‰1: 42 years,"/>
  <result pre="âœ&quot; Viral loads reduced109 Tofacitinib HTLV-1 âœ&quot; Prolong survival duration110" exact="Thalidomide" post="HHV-8 âœ&quot; Phase II (nâ€‰=â€‰17): 35% partial response rate111âœ&quot;"/>
  <result pre="and 10% stable disease112 AD, atopic dermatitis; CMV, cytomegalovirus; CsA," exact="cyclosporine" post="A; DENV, dengue virus; DMARDs, disease-modifying anti-rheumatic drugs; HAART,"/>
  <result pre="cell lymphotrophic virus-1; MERS-CoV, Middle East respiratory syndrome coronavirus; MMF," exact="mycophenolate mofetil;" post="PCT, porphyria cutanea tarda; RCT, randomized-controlled trial; RSV, respiratory"/>
  <result pre="virus; RNA, ribonucleic acid; SARS-CoV, severe acute respiratory syndrome coronavirus." exact="Leflunomide" post="Leflunomide is approved for rheumatoid arthritis and psoriatic arthritis"/>
  <result pre="RNA, ribonucleic acid; SARS-CoV, severe acute respiratory syndrome coronavirus. Leflunomide" exact="Leflunomide" post="is approved for rheumatoid arthritis and psoriatic arthritis (not"/>
  <result pre="rheumatoid arthritis and psoriatic arthritis (not in the United States)." exact="Leflunomide" post="inhibits the synthesis of pyrimidine via acting on the"/>
  <result pre="dividing cells, especially lymphocytes, are suppressed. On the other hand," exact="leflunomide" post="showed antiviral activity at least for CMV, BKV, and"/>
  <result pre="HSV-2 lesions in an acyclovir-resistant HIV patient significantly improved with" exact="leflunomide" post="40â€‰mg, twice a day.98 Another HIV patient with HSV-1/HSV-2"/>
  <result pre="9â€‰months of leflunomide, complete regression of the lesions was noted." exact="Leflunomide" post="has both immunomodulation and antiviral activities in the HSV"/>
  <result pre="in HIV patients.99 Human immunodeficiency virus An RCT (nâ€‰=â€‰18) demonstrated" exact="leflunomide" post="decreased the activation and cycling of CD4+ T cells."/>
  <result pre="Molluscum and verruca Three patients with atopic dermatitis treated with" exact="azathioprine" post="developed multiple verrucae and molluscum contagiosum. Due to treatment"/>
  <result pre="developed multiple verrucae and molluscum contagiosum. Due to treatment resistance," exact="azathioprine" post="was switched to leflunomide (100â€‰mg loading 3â€‰days, then 20â€‰mg/day)."/>
  <result pre="molluscum contagiosum. Due to treatment resistance, azathioprine was switched to" exact="leflunomide" post="(100â€‰mg loading 3â€‰days, then 20â€‰mg/day). All the lesions subsided"/>
  <result pre="All the lesions subsided in three patients within 2â€‰months of" exact="leflunomide" post="treatment.103 Multiple recalcitrant verrucae in three and molluscum in"/>
  <result pre="renal allograft recipients cleared after switching from MMF to leflunomide.104" exact="Leflunomide" post="can serve as a potential option for patients with"/>
  <result pre="was given. The result showed 15 patients (88%) responded to" exact="leflunomide" post="with involved organ healing and viremia clearance.113 Leflunomide was"/>
  <result pre="responded to leflunomide with involved organ healing and viremia clearance.113" exact="Leflunomide" post="was regarded as an add-on treatment for multi-drug-resistance CMV"/>
  <result pre="treatment for multi-drug-resistance CMV infection. In vitro anti-CMV properties of" exact="leflunomide" post="were not through blocking the replication of viral DNA,"/>
  <result pre="the administration of potent immunosuppressants such as MMF and tacrolimus." exact="Leflunomide" post="is now generally accepted as a second choice after"/>
  <result pre="II RCT (nâ€‰=â€‰46), viremia was decreased in the group of" exact="leflunomide" post="active metabolites, but no significant improvement of renal function"/>
  <result pre="Treatment options for RSV are limited to supportive care or" exact="ribavirin" post="with only marginal effectiveness. Leflunomide showed a potent, dose-dependent"/>
  <result pre="limited to supportive care or ribavirin with only marginal effectiveness." exact="Leflunomide" post="showed a potent, dose-dependent anti-RSV activity in cell cultures.92"/>
  <result pre="cotton rats, even if there was a 3-day delay of" exact="leflunomide" post="administration after viral inoculation.109 Leflunomide offers a dual benefit"/>
  <result pre="was a 3-day delay of leflunomide administration after viral inoculation.109" exact="Leflunomide" post="offers a dual benefit of both viral-load reduction and"/>
  <result pre="uveitis. Ex vivo and animal studies revealed positive results of" exact="tofacitinib" post="for ATLL and HAM.110 HTLV-1-encoded tax protein activates IL-2,"/>
  <result pre="of JAK3 in the pathophysiology of ATLL.114 As a result," exact="tofacitinib" post="targeting JAK3 has been suggested as a therapeutic strategy"/>
  <result pre="has been suggested as a therapeutic strategy in future studies." exact="Hydroxyurea" post="Hydroxyurea, a deoxyribonucleic acid (DNA)-synthesis inhibitor, belongs to the"/>
  <result pre="major and common adverse effect of hydroxyurea. Human immunodeficiency virus" exact="Hydroxyurea" post="demonstrated promising results in reducing HIV RNA viral loads"/>
  <result pre="loads in five placebo-controlled clinical trials. Among all the trials," exact="hydroxyurea" post="was combined with didanosine, a nucleoside analog reverse-transcriptase inhibitor"/>
  <result pre="In vitro studies demonstrated the antiviral modes of hydroxyurea. First," exact="hydroxyurea" post="depletes deoxynucleoside triphosphate (dNTP) pools, which impedes DNA synthesis"/>
  <result pre="in turn slows down the production of viral DNA. Second," exact="hydroxyurea" post="enhances NRTI phosphorylation and reduces resistance to NRTIs. This"/>
  <result pre="to NRTIs. This may partially explain the benefits of adding" exact="hydroxyurea" post="to NRTI for viral control. Finally, cytotoxic effect of"/>
  <result pre="hydroxyurea to NRTI for viral control. Finally, cytotoxic effect of" exact="hydroxyurea" post="makes cellular division of CD4+ T cells decline. This"/>
  <result pre="makes cellular division of CD4+ T cells decline. This enables" exact="hydroxyurea" post="to block HIV proliferation, because HIV could only replicate"/>
  <result pre="(HSV), parvovirus B19 (B19V) Although the mode of action of" exact="hydroxyurea" post="for HCV, HBV, HSV, and B19V is unknown, viral"/>
  <result pre="HSV, and B19V is unknown, viral replications were inhibited by" exact="hydroxyurea" post="in in vitro studies.70,74â€&quot;76 Small-scaled clinical trials showed significant"/>
  <result pre="of blood transfusion and attenuation of clinical symptoms when using" exact="hydroxyurea" post="in patients with B19V infection.77 Minocycline Minocycline, a second-generation"/>
  <result pre="minocycline caused the exacerbation of encephalomyelitis and higher mortality rate.92" exact="Chloroquine" post="and hydroxychloroquine Severe acute respiratory syndrome coronavirus (SARS-CoV) CQ"/>
  <result pre="the exacerbation of encephalomyelitis and higher mortality rate.92 Chloroquine and" exact="hydroxychloroquine" post="Severe acute respiratory syndrome coronavirus (SARS-CoV) CQ and HCQ"/>
  <result pre="transplantation. Earlier and more severe recurrence of PBC occurred with" exact="tacrolimus" post="compared with CsA as an immunosuppressant. This may be"/>
  <result pre="viral protein synthesis, gag and envelope assembly, and particle budding.63" exact="Mycophenolate mofetil" post="and mycophenolic acid Human immunodeficiency virus The combination of"/>
  <result pre="gag and envelope assembly, and particle budding.63 Mycophenolate mofetil and" exact="mycophenolic acid" post="Human immunodeficiency virus The combination of MMF and highly"/>
  <result pre="all marmosets treated with MMF experienced severe and fatal disease.96" exact="Thalidomide" post="Human herpesvirus 8 (HHV-8) HHV-8 is the cause of"/>
  <result pre="of Kaposiâ€™s sarcoma (KS). Case reports showed encouraging experience of" exact="thalidomide" post="in all types of KS (classic, iatrogenic, and HIV"/>
  <result pre="of HHV-8 were decreased in all patients.111,112 The effectiveness of" exact="thalidomide" post="for KS might be related to anti-angiogenesis, and experts"/>
  <result pre="ahead of print 2722020 DOI: 10.1016/j.apsb.2020.02.008. 4Al-BariMAATargeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
  <result pre="diseases. Pharmacol Res Perspect2017; 5: e00293.28596841 5WangMCaoRZhangL, et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="novel coronavirus (2019-nCoV) in vitro. Cell Res2020; 30: 269â€&quot;271.32020029 6GaoJTianZYangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  <result pre="clinical studies. Biosci Trends2020; 14: 72â€&quot;73.32074550 7GautretPLagierJCParolaP, et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="print 2032020. DOI: 1016/j.ijantimicag.2020.105949. 8ChenJLiuDLiuL, et al.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with moderate COVID-19. Zhejiang Da"/>
  <result pre="9GautretPLagierJCParolaP, et al.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
  <result pre="al.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
  <result pre="Travel Med Infect Dis2020; 34: 101663.32289548 10ChenZHuJZhangZ, et al.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
  <result pre="Dis. Epub ahead of print 342020 DOI: 10.1016/S1473-3099(20)30270-X. 22Sanchez-PernauteORomero-BuenoFISelva-Oâ€™CallaghanA.Why choose" exact="cyclosporin A" post="as first-line therapy in COVID-19 pneumonia. Reumatol Clin. Epub"/>
  <result pre="Nature2005; 434: 658â€&quot;662.15800627 25GoDJParkJKKangEH, et al.Survival benefit associated with early" exact="cyclosporine" post="treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int2016; 36:"/>
  <result pre="lung disease. Rheumatol Int2016; 36: 125â€&quot;131.26223808 26GarcÃ­aFPlanaMArnedoM, et al.Effect of" exact="mycophenolate mofetil" post="on immune response and plasma and lymphatic tissue viral"/>
  <result pre="US National Library of Medicine. The efficacy and safety of" exact="thalidomide" post="in the adjuvant treatment of moderate new coronavirus (COVID-19)"/>
  <result pre="additive in vitro anti-HIV-1 effect of chloroquine, when combined with" exact="zidovudine" post="and hydroxyurea. Biochem Pharmacol2001; 61: 1531â€&quot;1535.11377382 35SperberKLouieMKrausT, et al.Hydroxychloroquine"/>
  <result pre="type 1. Clin Ther1995; 17: 622â€&quot;636.8565026 36NeelyMKalyesubulaIBagendaD, et al.Effect of" exact="chloroquine" post="on human immunodeficiency virus (HIV) vertical transmission. Afr Health"/>
  <result pre="Sci2003; 3: 61â€&quot;67.12913796 37MurraySMDownCMBoulwareDR, et al.Reduction of immune activation with" exact="chloroquine" post="therapy during chronic HIV infection. J Virol2010; 84: 12082â€&quot;12086.20844049"/>
  <result pre="therapy-treated immunologic nonresponders. Blood2011; 118: 3263â€&quot;3272.21576701 39PatonNIGoodallRLDunnDT, et al.Effects of" exact="hydroxychloroquine" post="on immune activation and disease progression among HIV-infected patients"/>
  <result pre="randomized controlled trial. JAMA2012; 308: 353â€&quot;361.22820788 40RoutyJPAngelJBPatelM, et al.Assessment of" exact="chloroquine" post="as a modulator of immune activation to improve CD4"/>
  <result pre="C6/36 cells. ScientificWorldJournal2013; 2013: 282734.23431254 42FariasKJMachadoPRMunizJA, et al.Antiviral activity of" exact="chloroquine" post="against dengue virus type 2 replication in Aotus monkeys."/>
  <result pre="Cruz2013; 108: 596â€&quot;599.23903975 44TricouVMinhNNVanTP, et al.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adults. PLoS"/>
  <result pre="66: 217â€&quot;218.6087474 47De LamballerieXBoissonVReynierJC, et al.On chikungunya acute infection and" exact="chloroquine" post="treatment. Vector Borne Zoonotic Dis2008; 8: 837â€&quot;839.18620511 48FedsonDS.Confronting an"/>
  <result pre="be done?Lancet Infect Dis2008; 8: 571â€&quot;576.18420459 49YanYZouZSunY, et al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
  <result pre="et al.Long-term follow-up of HIV positive asymptomatic patients having received" exact="cyclosporin A." post="Adv Exp Med Biol1995; 374: 229â€&quot;234.7572396 57CalabreseLHLedermanMMSpritzlerJ, et al.Placebo-controlled"/>
  <result pre="Mol Cell2005; 19: 111â€&quot;122.15989969 60InoueKSekiyamaKYamadaM, et al.Combined interferon alpha2b and" exact="cyclosporin A" post="in the treatment of chronic hepatitis C: controlled trial."/>
  <result pre="cirrhosis. Liver Int2010; 30: 871â€&quot;877.20492501 64LoriFLisziewiczJ.Rationale for the use of" exact="hydroxyurea" post="as an anti-human immunodeficiency virus drug. Clin Infect Dis2000;"/>
  <result pre="Hum Retroviruses1997; 13: 1403â€&quot;1409.9359660 66RutschmannOTOpravilMItenA, et al.A placebo-controlled trial of" exact="didanosine" post="plus stavudine, with and without hydroxyurea, for HIV infection."/>
  <result pre="combination of reverse transcriptase inhibitors versus the same regimen plus" exact="hydroxyurea" post="or hydroxyurea and interleukin-2 in HIV-infected patients failing protease"/>
  <result pre="reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or" exact="hydroxyurea" post="and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations."/>
  <result pre="3: 263â€&quot;271.12187499 68FrankIBoschRJFiscusS, et al.Activity, safety, and immunological effects of" exact="hydroxyurea" post="added to didanosine in antiretroviral-naive and experienced HIV type"/>
  <result pre="et al.Activity, safety, and immunological effects of hydroxyurea added to" exact="didanosine" post="in antiretroviral-naive and experienced HIV type 1-infected subjects: a"/>
  <result pre="69StebbingJNelsonMOrkinC, et al.A randomized trial to investigate the recycling of" exact="stavudine" post="and didanosine with and without hydroxyurea in salvage therapy"/>
  <result pre="al.A randomized trial to investigate the recycling of stavudine and" exact="didanosine" post="with and without hydroxyurea in salvage therapy (RESTART). J"/>
  <result pre="investigate the recycling of stavudine and didanosine with and without" exact="hydroxyurea" post="in salvage therapy (RESTART). J Antimicrob Chemother2004; 53: 501â€&quot;505.14762056"/>
  <result pre="HCV replication in humans: a phase I trial of oral" exact="hydroxyurea" post="in chronic hepatitis C patients. Antivir Ther2010; 15: 1179â€&quot;1183.21149925"/>
  <result pre="patients. Antivir Ther2010; 15: 1179â€&quot;1183.21149925 72KashaniHHVossoughiAAdibiP, et al.Amazing results with" exact="hydroxyurea" post="therapy in chronic hepatitis B: a preliminary report. Hepat"/>
  <result pre="73WatanabeNYasudaHAotaY, et al.Reactivation of hepatitis B virus during treatment with" exact="hydroxyurea" post="in an elderly patient with essential thrombocythemia. Geriatr Gerontol"/>
  <result pre="Antimicrob Agents Chemother1973; 3: 325â€&quot;331.4364174 75SergerieYBoivinG.Hydroxyurea enhances the activity of" exact="acyclovir" post="and cidofovir against herpes simplex virus type 1 resistant"/>
  <result pre="Chemother1973; 3: 325â€&quot;331.4364174 75SergerieYBoivinG.Hydroxyurea enhances the activity of acyclovir and" exact="cidofovir" post="against herpes simplex virus type 1 resistant strains harboring"/>
  <result pre="B19 infection in children with sickle cell disease in the" exact="hydroxyurea" post="era. Exp Biol Med (Maywood)2016; 241: 749â€&quot;754.26940953 78SiQCosenzaMKimMO, et"/>
  <result pre="mice. J Virol2007; 81: 6248â€&quot;6253.17409147 93ChapuisAGPaolo RizzardiGDâ€™AgostinoC, et al.Effects of" exact="mycophenolic acid" post="on human immunodeficiency virus infection in vitro and in"/>
  <result pre="treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with" exact="leflunomide" post="in an HIV-infected man. J Clin Virol2012; 54: 276â€&quot;278.22465339"/>
  <result pre="199â€&quot;201.11588518 101SchlapferEFischerMOttP, et al.Anti-HIV-1 activity of leflunomide: a comparison with" exact="mycophenolic acid" post="and hydroxyurea. AIDS2003; 17: 1613â€&quot;1620.12853743 102ReadSWDeGreziaMCicconeEJ, et al.The effect"/>
  <result pre="and hydroxyurea. AIDS2003; 17: 1613â€&quot;1620.12853743 102ReadSWDeGreziaMCicconeEJ, et al.The effect of" exact="leflunomide" post="on cycling and activation of T-cells in HIV-1-infected participants."/>
  <result pre="14: 111â€&quot;120.22093814 106ChongASZengHKnightDA, et al.Concurrent antiviral and immunosuppressive activities of" exact="leflunomide" post="in vivo. Am J Transplant2006; 6: 69â€&quot;75.16433758 107VerkaikNJHoekRAVan BergeijkH,"/>
  <result pre="ATL and HAM/TSP. Blood2011; 117: 1938â€&quot;1946.21106989 111FifeKHowardMRGracieF, et al.Activity of" exact="thalidomide" post="in AIDS-related Kaposiâ€™s sarcoma and correlation with HHV8 titre."/>
  <result pre="Int J STD AIDS1998; 9: 751â€&quot;755.9874123 112LittleRFWyvillKMPludaJM, et al.Activity of" exact="thalidomide" post="in AIDS-related Kaposiâ€™s sarcoma. J Clin Oncol2000; 18: 2593â€&quot;2602.10893291"/>
  <result pre="Clin Oncol2000; 18: 2593â€&quot;2602.10893291 113JohnGTManivannanJChandyS, et al.A prospective evaluation of" exact="leflunomide" post="therapy for cytomegalovirus disease in renal transplant recipients. Transplant"/>
 </snippets>
</snippetsTree>
